Our results indicated a negative correlation between CD8 and SLC25A5, and the patients in the high-risk group showed higher immune infiltration and lower levels of glycolysis and cell apoptosis, which seemed contradictory to previous findings that increased tumor-infiltrating CD8+ lymphocytes were normally related to survival benefit in patients with cancer [26]. This evidence concerns the gene SLC25A5 and cancer.